BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Howells A, Marelli G, Lemoine NR, Wang Y. Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer. Front Oncol 2017;7:195. [PMID: 28944214 DOI: 10.3389/fonc.2017.00195] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 15.8] [Reference Citation Analysis]
Number Citing Articles
1 Trivanović D, Peršurić Ž, Agaj A, Jakopović M, Samaržija M, Bitar L, Pavelić K. The Interplay of Lung Cancer, COVID-19, and Vaccines. IJMS 2022;23:15067. [DOI: 10.3390/ijms232315067] [Reference Citation Analysis]
2 Shayan S, Arashkia A, Azadmanesh K. Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand? Cancer Cell Int 2022;22:370. [DOI: 10.1186/s12935-022-02774-w] [Reference Citation Analysis]
3 Seyed-khorrami S, Soleimanjahi H, Łos MJ, Zandi K, Emameh RZ. Oncolytic viruses as emerging therapy against cancers including Oncovirus-induced cancers. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175393] [Reference Citation Analysis]
4 Hassan ST, Mohamed AF, AbdelAllah NH, Zedan H. Evaluation of MMR live attenuated vaccine oncolytic potential using Ehrlich ascites carcinoma in a murine model. Med Oncol 2022;40:6. [PMID: 36308603 DOI: 10.1007/s12032-022-01866-x] [Reference Citation Analysis]
5 Zhu Z, McGray AJR, Jiang W, Lu B, Kalinski P, Guo ZS. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Mol Cancer 2022;21:196. [PMID: 36221123 DOI: 10.1186/s12943-022-01664-z] [Reference Citation Analysis]
6 Salman MI, Al-shammari AM, Emran MA. 3-Dimensional coculture of breast cancer cell lines with adipose tissue–Derived stem cells reveals the efficiency of oncolytic Newcastle disease virus infection via labeling technology. Front Mol Biosci 2022;9:754100. [DOI: 10.3389/fmolb.2022.754100] [Reference Citation Analysis]
7 Pellegrini S, Zamarian V, Sordi V. Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes. Transpl Int 2022;35:10575. [DOI: 10.3389/ti.2022.10575] [Reference Citation Analysis]
8 Lauer UM, Beil J. Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol 2022. [PMID: 35818970 DOI: 10.2217/fon-2022-0440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nono MK, Ngouonkadi EM, Bowong S, Fotsin H. Spatiotemporal dynamics and optimal control of glioma virotherapy enhanced by MEK Inhibitors. Results in Control and Optimization 2022;7:100101. [DOI: 10.1016/j.rico.2022.100101] [Reference Citation Analysis]
10 Wang L, Chard Dunmall LS, Cheng Z, Wang Y. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. J Immunother Cancer 2022;10:e004167. [PMID: 35640930 DOI: 10.1136/jitc-2021-004167] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Marek K, Armando F, Nippold VM, Rohn K, Plattet P, Brogden G, Gerold G, Baumgärtner W, Puff C. Persistent Infection of a Canine Histiocytic Sarcoma Cell Line with Attenuated Canine Distemper Virus Expressing Vasostatin or Granulocyte-Macrophage Colony-Stimulating Factor. IJMS 2022;23:6156. [DOI: 10.3390/ijms23116156] [Reference Citation Analysis]
12 Yolles M, Frieden R. Viruses as Living Systems—A Metacybernetic View. Systems 2022;10:70. [DOI: 10.3390/systems10030070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hu H, Zhang S, Cai L, Duan H, Li Y, Yang J, Wang Y, Liu B, Dong S, Fang Z, Liu B. A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy. Virol J 2022;19:74. [PMID: 35459242 DOI: 10.1186/s12985-022-01795-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hamidi-sofiani V, Rakhshi R, Moradi N, Zeynali P, Nakhaie M, Behboudi E. Oncolytic viruses and pancreatic cancer. Cancer Treatment and Research Communications 2022. [DOI: 10.1016/j.ctarc.2022.100563] [Reference Citation Analysis]
15 Chaudhary H, D'Angelo S. Role of Virus-Directed Therapy in Soft Tissue Sarcoma. Curr Treat Options Oncol 2022. [PMID: 35258792 DOI: 10.1007/s11864-022-00956-2] [Reference Citation Analysis]
16 Verhulst E, Garnier D, De Meester I, Bauvois B. Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go? Cancers (Basel) 2022;14:624. [PMID: 35158891 DOI: 10.3390/cancers14030624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Zuo S, Wei M, Xu T, Kong L, He B, Wang S, Wang S, Wu J, Dong J, Wei J. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade. J Immunother Cancer 2021;9:e002843. [PMID: 34949694 DOI: 10.1136/jitc-2021-002843] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
18 Bukhari B, Naveed M, Makhdoom SI, Jabeen K, Asif MF, Batool H, Ahmed N, Chan YY. A Comparison Between Organic and Inorganic Nanoparticles: Prime Nanoparticles for Tumor Curation. NANO 2021;16:2130011. [DOI: 10.1142/s1793292021300115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Rolfo C, Meshulami N, Russo A, Krammer F, García-Sastre A, Mack PC, Gomez JE, Bhardwaj N, Benyounes A, Sirera R, Moore A, Rohs N, Henschke CI, Yankelevitz D, King J, Shyr Y, Bunn PA Jr, Minna JD, Hirsch FR. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. J Thorac Oncol 2021:S1556-0864(21)03309-8. [PMID: 34774792 DOI: 10.1016/j.jtho.2021.11.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
20 Chugh V, Vijaya Krishna K, Pandit A. Cell Membrane-Coated Mimics: A Methodological Approach for Fabrication, Characterization for Therapeutic Applications, and Challenges for Clinical Translation. ACS Nano 2021. [PMID: 34699181 DOI: 10.1021/acsnano.1c03800] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 15.0] [Reference Citation Analysis]
21 Wang Z, Zhang X. Adenovirus vector-attributed hepatotoxicity blocks clinical application in gene therapy. Cytotherapy 2021;23:1045-52. [PMID: 34548241 DOI: 10.1016/j.jcyt.2021.07.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
22 Piperno A, Sciortino MT, Giusto E, Montesi M, Panseri S, Scala A. Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles. Int J Nanomedicine 2021;16:5981-6002. [PMID: 34511901 DOI: 10.2147/IJN.S321329] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
23 Ahmadi A, Ghaleh HE, Dorostkar R, Farzanehpour M, Bolandian M. Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review. CCTR 2021;17:173-8. [DOI: 10.2174/1573394716999201228215537] [Reference Citation Analysis]
24 AuYeung AWK, Mould RC, Stegelmeier AA, van Vloten JP, Karimi K, Woods JP, Petrik JJ, Wood GA, Bridle BW. Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis. Sci Rep 2021;11:15290. [PMID: 34315959 DOI: 10.1038/s41598-021-94483-z] [Reference Citation Analysis]
25 Aghlara-Fotovat S, Nash A, Kim B, Krencik R, Veiseh O. Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies. Drug Deliv Transl Res 2021. [PMID: 34176099 DOI: 10.1007/s13346-021-01018-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Rico J, Perez C, Hernandez J, Guerrero C, Acosta O. Cell surface heat shock protein-mediated entry of tumor cell-adapted rotavirus into U-937 cells. Folia Microbiol (Praha) 2021;66:623-38. [PMID: 33950511 DOI: 10.1007/s12223-020-00845-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yuan Z, Fan X, Zhu JJ, Fu TM, Wu J, Xu H, Zhang N, An Z, Zheng WJ. Presence of complete murine viral genome sequences in patient-derived xenografts. Nat Commun 2021;12:2031. [PMID: 33795676 DOI: 10.1038/s41467-021-22200-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Perez C, Rico J, Guerrero C, Acosta O. Role of heat-shock proteins in infection of human adenocarcinoma cell line MCF-7 by tumor-adapted rotavirus isolates. Colomb Med (Cali) 2021;52:e2024196. [PMID: 33911319 DOI: 10.25100/cm.v51i4.4196] [Reference Citation Analysis]
29 Brouwer TP, Vahrmeijer AL, de Miranda NFCC. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cell Oncol (Dordr) 2021;44:261-78. [PMID: 33710604 DOI: 10.1007/s13402-021-00587-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
30 Marchica V, Costa F, Donofrio G, Giuliani N. Oncolytic Virotherapy and Microenvironment in Multiple Myeloma. Int J Mol Sci 2021;22:2259. [PMID: 33668361 DOI: 10.3390/ijms22052259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Martinez-Perez AG, Perez-Trujillo JJ, Garza-Morales R, Ramirez-Avila NE, Loera-Arias MJ, Gomez-Gutierrez JG, Saucedo-Cardenas O, Garcia-Garcia A, Rodriguez-Rocha H, Montes-de-Oca-Luna R. An Oncolytic Adenovirus Encoding SA-4-1BBL Adjuvant Fused to HPV-16 E7 Antigen Produces a Specific Antitumor Effect in a Cancer Mouse Model. Vaccines (Basel) 2021;9:149. [PMID: 33673295 DOI: 10.3390/vaccines9020149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
32 Singh HK, Pandey DN. Stability analysis of a fractional‐order delay dynamical model on oncolytic virotherapy. Math Meth Appl Sci 2021;44:1377-93. [DOI: 10.1002/mma.6836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Chen T, Ding X, Liao Q, Gao N, Chen Y, Zhao C, Zhang X, Xu J. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. J Immunother Cancer 2021;9:e001647. [PMID: 33504576 DOI: 10.1136/jitc-2020-001647] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
34 Dahariya S, Nagarjuna V. Biomaterials in Tissue Engineering and Regenerative Medicine: In Vitro Disease Models and Advances in Gene-Based Therapies. Biomaterials in Tissue Engineering and Regenerative Medicine 2021. [DOI: 10.1007/978-981-16-0002-9_14] [Reference Citation Analysis]
35 Yoshida H, Sato-Dahlman M, Hajeri P, Jacobsen K, Koodie L, Yanagiba C, Shanley R, Yamamoto M. Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells. Transl Oncol 2021;14:100997. [PMID: 33338875 DOI: 10.1016/j.tranon.2020.100997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Watanabe N, McKenna MK, Rosewell Shaw A, Suzuki M. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Mol Ther 2021;29:505-20. [PMID: 33130314 DOI: 10.1016/j.ymthe.2020.10.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 10.5] [Reference Citation Analysis]
37 Aligholipour Farzani T, Bilge Dagalp S, Ozkul A, Gurdal H, Dogan F, Alkan F. Assessment of replication of bovine herpesvirus type 4 in human glioblastoma and breast cancer cells as a potential oncolytic virus. Virus Genes 2021;57:31-9. [PMID: 33104955 DOI: 10.1007/s11262-020-01802-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Rius-Rocabert S, García-Romero N, García A, Ayuso-Sacido A, Nistal-Villan E. Oncolytic Virotherapy in Glioma Tumors.Int J Mol Sci. 2020;21. [PMID: 33066689 DOI: 10.3390/ijms21207604] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
39 Iannuzzi CA, Indovina P, Forte IM, Di Somma S, Malfitano AM, Bruno M, Portella G, Pentimalli F, Giordano A. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines. Int J Mol Sci 2020;21:E7333. [PMID: 33020398 DOI: 10.3390/ijms21197333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
40 Moussa M, Papatsoris AG, Dellis A, Abou Chakra M, Saad W. Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2020;20:965-83. [PMID: 32915676 DOI: 10.1080/14737140.2020.1822743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Lathwal A, Kumar R, Raghava GP. OvirusTdb: A database of oncolytic viruses for the advancement of therapeutics in cancer. Virology 2020;548:109-16. [DOI: 10.1016/j.virol.2020.05.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
42 Hu PY, Fan XM, Zhang YN, Wang SB, Wan WJ, Pan HY, Mou XZ. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them. Appl Microbiol Biotechnol 2020;104:8231-42. [PMID: 32816087 DOI: 10.1007/s00253-020-10802-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Mozaffari Nejad AS, Fotouhi F, Mehrbod P, Keshavarz M, Alikhani MY, Ghaemi A. Oncolytic effects of Hitchner B1 strain of newcastle disease virus against cervical cancer cell proliferation is mediated by the increased expression of cytochrome C, autophagy and apoptotic pathways. Microb Pathog 2020;147:104438. [PMID: 32777353 DOI: 10.1016/j.micpath.2020.104438] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
44 Gilchrist VH, Jémus-Gonzalez E, Said A, Alain T. Kinase inhibitors with viral oncolysis: Unmasking pharmacoviral approaches for cancer therapy. Cytokine Growth Factor Rev 2020;56:83-93. [PMID: 32690442 DOI: 10.1016/j.cytogfr.2020.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Guo ZS, Lotze MT, Zhu Z, Storkus WJ, Song XT. Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy. Biomedicines 2020;8:E204. [PMID: 32664210 DOI: 10.3390/biomedicines8070204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
46 Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. J Leukoc Biol. 2020;108:1455-1489. [PMID: 32557857 DOI: 10.1002/jlb.5bt0420-585rr] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
47 Guerrero RA, Guerrero CA, Guzmán F, Acosta O. Assessing the oncolytic potential of rotavirus on mouse myeloma cell line Sp2/0-Ag14. Biomedica 2020;40:362-81. [PMID: 32673463 DOI: 10.7705/biomedica.4916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Terrível M, Gromicho C, Matos AM. Oncolytic viruses: what to expect from their use in cancer treatment. Microbiol Immunol 2020;64:477-92. [PMID: 31663631 DOI: 10.1111/1348-0421.12753] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
49 Simbawa E, Al-Johani N, Al-Tuwairqi S. Modeling the Spatiotemporal Dynamics of Oncolytic Viruses and Radiotherapy as a Treatment for Cancer. Comput Math Methods Med 2020;2020:3642654. [PMID: 32411281 DOI: 10.1155/2020/3642654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
50 Zhang W, Hu X, Liang J, Zhu Y, Zeng B, Feng L, Zhao C, Liu S, Liu B, Zhang K. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity. Mol Ther Oncolytics 2020;16:158-71. [PMID: 32055679 DOI: 10.1016/j.omto.2019.12.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
51 McKenna MK, Rosewell-Shaw A, Suzuki M. Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives. Cancers (Basel) 2020;12:E619. [PMID: 32155969 DOI: 10.3390/cancers12030619] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
52 Lan Q, Xia S, Wang Q, Xu W, Huang H, Jiang S, Lu L. Development of oncolytic virotherapy: from genetic modification to combination therapy. Front Med 2020;14:160-84. [PMID: 32146606 DOI: 10.1007/s11684-020-0750-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
53 Jayawardena N, Poirier JT, Burga LN, Bostina M. Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development. Oncolytic Virother 2020;9:1-15. [PMID: 32185149 DOI: 10.2147/OV.S186337] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
54 Russell L, Peng KW, Russell SJ, Diaz RM. Oncolytic Viruses: Priming Time for Cancer Immunotherapy. BioDrugs 2019;33:485-501. [PMID: 31321623 DOI: 10.1007/s40259-019-00367-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 31.0] [Reference Citation Analysis]
55 Jeevanandam J, Tan KX, Danquah MK, Guo H, Turgeson A. Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications-The Role of Molecular Dynamics Simulation. Biotechnol J 2020;15:e1900368. [PMID: 31840436 DOI: 10.1002/biot.201900368] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
56 Kambouris ME. Culturomics: The Alternative From the Past. Microbiomics 2020. [DOI: 10.1016/b978-0-12-816664-2.00008-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Withers SS, Sparger EE, Boudreaux B, Mason NJ. Utilizing Microbes to Treat Naturally Occurring Cancer in Veterinary Species. Curr Clin Micro Rpt 2019;6:200-12. [DOI: 10.1007/s40588-019-00130-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel) 2019;11:E1926. [PMID: 31816940 DOI: 10.3390/cancers11121926] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
59 Luo Y, Lin C, Ren W, Ju F, Xu Z, Liu H, Yu Z, Chen J, Zhang J, Liu P, Huang C, Xia N. Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma. Mol Ther Oncolytics 2019;15:153-65. [PMID: 31720372 DOI: 10.1016/j.omto.2019.09.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
60 Kwon S. The Trend in the Development of Oncolytic Virus Therapy. BSL 2019;25:201-210. [DOI: 10.15616/bsl.2019.25.3.201] [Reference Citation Analysis]
61 Araghi A, Hashemi S, Sepahi AA, Faramarzi MA, Amin M. Purification and study of anti-cancer effects of Serratia marcescens serralysin. Iran J Microbiol 2019;11:320-7. [PMID: 31719964] [Reference Citation Analysis]
62 Fu LQ, Wang SB, Cai MH, Wang XJ, Chen JY, Tong XM, Chen XY, Mou XZ. Recent advances in oncolytic virus-based cancer therapy.Virus Res. 2019;270:197675. [PMID: 31351879 DOI: 10.1016/j.virusres.2019.197675] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
63 Al-anazi* KA, Wk A, Am A. The beneficial effects of varicella zoster virus. J Hematol Clin Res 2019;3:016-049. [DOI: 10.29328/journal.jhcr.1001010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Di Somma S, Iannuzzi CA, Passaro C, Forte IM, Iannone R, Gigantino V, Indovina P, Botti G, Giordano A, Formisano P, Portella G, Malfitano AM, Pentimalli F. The Oncolytic Virus dl922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth. Front Oncol 2019;9:564. [PMID: 31355131 DOI: 10.3389/fonc.2019.00564] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
65 Cai R, Meng G, Li Y, Wang W, Diao Y, Zhao S, Feng Q, Tang Y. The oncolytic efficacy and safety of avian reovirus and its dynamic distribution in infected mice. Exp Biol Med (Maywood) 2019;244:983-91. [PMID: 31299861 DOI: 10.1177/1535370219861928] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
66 Ka* A, Am A. Varicella zoster virus: The potentially useful virus. J Hematol Clin Res 2019;3:011-015. [DOI: 10.29328/journal.jhcr.1001009] [Reference Citation Analysis]
67 Aijaz A, Vaninov N, Allen A, Barcia RN, Parekkadan B. Convergence of Cell Pharmacology and Drug Delivery. Stem Cells Transl Med 2019;8:874-9. [PMID: 31091020 DOI: 10.1002/sctm.19-0019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
68 Al-anazi K, Kanfar S, Aldayel A, Abduljalil O, Sayyed A. Reversal of pure red cell aplasia by varicella zoster virus infection. J Hematol Clin Res 2019;3:001-010. [DOI: 10.29328/journal.jhcr.1001008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
69 Raman SS, Hecht JR, Chan E. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy 2019;11:705-23. [PMID: 31045464 DOI: 10.2217/imt-2019-0033] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 16.3] [Reference Citation Analysis]
70 Kellish P, Shabashvili D, Rahman MM, Nawab A, Guijarro MV, Zhang M, Cao C, Moussatche N, Boyle T, Antonia S, Reinhard M, Hartzell C, Jantz M, Mehta HJ, McFadden G, Kaye FJ, Zajac-Kaye M. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. J Clin Invest 2019;129:2279-92. [PMID: 31033480 DOI: 10.1172/JCI121323] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
71 Sivanandam V, LaRocca CJ, Chen NG, Fong Y, Warner SG. Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds.Mol Ther Oncolytics. 2019;13:93-106. [PMID: 31080879 DOI: 10.1016/j.omto.2019.04.003] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 27.3] [Reference Citation Analysis]
72 Sung YK, Kim SW. Recent advances in the development of gene delivery systems. Biomater Res. 2019;23:8. [PMID: 30915230 DOI: 10.1186/s40824-019-0156-z] [Cited by in Crossref: 163] [Cited by in F6Publishing: 172] [Article Influence: 54.3] [Reference Citation Analysis]
73 Garofalo M, Villa A, Rizzi N, Kuryk L, Rinner B, Cerullo V, Yliperttula M, Mazzaferro V, Ciana P. Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. Journal of Controlled Release 2019;294:165-75. [DOI: 10.1016/j.jconrel.2018.12.022] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 21.7] [Reference Citation Analysis]
74 Goradel NH, Mohajel N, Malekshahi ZV, Jahangiri S, Najafi M, Farhood B, Mortezaee K, Negahdari B, Arashkia A. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches. J Cell Physiol 2019;234:8636-46. [PMID: 30515798 DOI: 10.1002/jcp.27850] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
75 Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, Airaksinen AJ, Cervera-Carrascon V, Tähtinen S, Kanerva A, Hemminki A. Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus. Mol Ther Oncolytics 2018;11:109-21. [PMID: 30569015 DOI: 10.1016/j.omto.2018.10.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
76 Passaro C, Somma SD, Malfitano AM, Portella G. Oncolytic virotherapy for anaplastic and poorly differentiated thyroid cancer: a promise or a clinical reality? International Journal of Endocrine Oncology 2018;5:IJE10. [DOI: 10.2217/ije-2017-0028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Wang M, Hong Y, Feng Q, Pan X, Song S, Cui J, Lei J, Fang H, Yang J. Recombinant Adenovirus KGHV500 and CIK Cells Codeliver Anti-p21-Ras scFv for the Treatment of Gastric Cancer with Wild-Type Ras Overexpression. Mol Ther Oncolytics 2018;11:90-101. [PMID: 30534583 DOI: 10.1016/j.omto.2018.10.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
78 Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. Oncoimmunology 2018;7:e1503032. [PMID: 30524901 DOI: 10.1080/2162402X.2018.1503032] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 14.3] [Reference Citation Analysis]
79 Arab A, Behravan N, Razazn A, Barati N, Mosaffa F, Nicastro J, Slavcev R, Behravan J. The viral approach to breast cancer immunotherapy. J Cell Physiol 2019;234:1257-67. [PMID: 30146692 DOI: 10.1002/jcp.27150] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
80 Bourhill T, Mori Y, Rancourt DE, Shmulevitz M, Johnston RN. Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection. Viruses 2018;10:E421. [PMID: 30103501 DOI: 10.3390/v10080421] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
81 Kuryk L, Møller AW, Garofalo M, Cerullo V, Pesonen S, Alemany R, Jaderberg M. Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. J Med Virol 2018;90:1669-73. [PMID: 29797583 DOI: 10.1002/jmv.25229] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
82 Barrett J. E pluribus unum: Combining Molecular Strategies to Defeat Head and Neck Cancer. Mol Ther 2017;25:2434-5. [PMID: 29055622 DOI: 10.1016/j.ymthe.2017.10.006] [Reference Citation Analysis]